COVID-19 vaccine reaches phase-2 trials in China
Xinhua |
Updated: 2020-06-20 21:11
Share
Share - WeChat
BEIJING - An inactivated COVID-19 vaccine candidate developed by the Institute of Medical Biology under the Chinese Academy of Medical Sciences has entered phase-2 clinical trials in China, the Science and Technology Daily reported Saturday.
The phase-2 trials, which further evaluate the immunogenicity and safety of the vaccine in humans, are conducted in the southwestern province of Yunnan.
So far, five COVID-19 vaccine candidates have been approved for clinical trials in China, accounting for 40 percent of the total vaccines in clinical trials worldwide, according to the Ministry of Science and Technology.
- China hands over 17 Filipino sailors from shipwreck to Philippines
- Topography, extreme rainfall causes of Guizhou landslide, report says
- Various activities held to welcome upcoming Laba Festival
- Beijing plans further expansion of its world-class metro network
- Xi leads China's diplomacy to usher in new chapter in turbulent world
- NEV surge contributes to record air quality improvement in Beijing
